Phase Ia/Ib Open Label, Multi-Centre Dose Escalation Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of DSB2455 as Monotherapy in Participants With Advanced Malignancies

Inclusion Criteria: * The participant (or legally acceptable representative, if applicable) provides written informed consent for the study. * Aged ≥18 years of age on the day of signing the informed consent. * Provision of formalin-fixed and paraffin embedded (FFPE) is mandatory. If an FFPE sample is not available prior to intervention, then a baseline fresh biopsy is required. * Has measurable disease per RECIST v1.1 * ECOG performance status of 0 to 1. * Life expectancy \>12 weeks. * Willing and able to comply with scheduled visits (including follow-up visits), treatment plan and laborator…